Tracer library / [161Tb]Tb-DOTA-IBA

[161Tb]Tb-DOTA-IBA

Also written as [161Tb]Tb-DOTA-IBA
Radionuclide
Tb-161
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
0
Bone metastases and bone lesionsOther radioligand therapy

What it is

Compound class
Bisphosphonate (ibandronate)-based DOTA conjugate for bone targeting
Target / mechanism
Bone mineral (hydroxyapatite) targeting via bisphosphonate PMID 42444557
Clinical application
Targeted radionuclide therapy for bone metastases PMID 42444557
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Unexpected Bilateral Lacrimal and Salivary Gland Uptake of 68 Ga-DOTA-Ibandronic Acid on PET/CT.
    2026 · Clin Nucl Med · Clinical study
  2. A case of sarcomatoid carcinoma of the lung treated with a new radiopharmaceutical 225Ac-DOTA-IBA.
    2026 · Clin Nucl Med · Clinical study

Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTA-IBA, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 3 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 41632578, 42341194, 42444557. Stage set/updated at stage 39 from PMID 42444557: 'a preliminary clinical evaluation was performed in one volunteer with bone metastases to validate safety and initial therapeutic efficacy'.